U12, a UDCA Derivative, Acts as an Anti-Hepatoma Drug Lead and Inhibits the mTOR/S6K1 and Cyclin/CDK Complex Pathways

• Yang Xu ,

  Contributed equally to this work with: Yang Xu, Qiang Luo

  Affiliation School of Pharmaceutical Sciences, Xiamen University, Xiamen, Fujian, PR China

  ⨯
• Qiang Luo ,

  Contributed equally to this work with: Yang Xu, Qiang Luo

  Affiliation School of Pharmaceutical Sciences, Xiamen University, Xiamen, Fujian, PR China

  ⨯
• Ting Lin,

  Affiliation School of Pharmaceutical Sciences, Xiamen University, Xiamen, Fujian, PR China

  ⨯
• Zhiping Zeng,

  Affiliation School of Pharmaceutical Sciences, Xiamen University, Xiamen, Fujian, PR China

  ⨯
• Guanghui Wang,

  Affiliation School of Pharmaceutical Sciences, Xiamen University, Xiamen, Fujian, PR China

  ⨯
• Dequan Zeng,

  Affiliation School of Pharmaceutical Sciences, Xiamen University, Xiamen, Fujian, PR China

  ⨯
• Rong Ding,

  Affiliation School of Pharmaceutical Sciences, Xiamen University, Xiamen, Fujian, PR China

  ⨯
• Cuiling Sun,

  Affiliation School of Pharmaceutical Sciences, Xiamen University, Xiamen, Fujian, PR China

  ⨯
• Xiao-kun Zhang ,

  * E-mail: xzhang@burnham.org (XZ); haifeng@xmu.edu.cn (HC)

  Affiliations School of Pharmaceutical Sciences, Xiamen University, Xiamen, Fujian, PR China, Sanford-Burnham Medical Research Institute, La Jolla, California, United States of America

  ⨯
• Haifeng Chen

  * E-mail: xzhang@burnham.org (XZ); haifeng@xmu.edu.cn (HC)

  Affiliation School of Pharmaceutical Sciences, Xiamen University, Xiamen, Fujian, PR China

  ⨯